Protein-protein interactions (PPIs) are involved in almost every cellular process. They represent attractive targets for modulating signaling pathways leading to disease states. However, they are challenging to target with small molecules, peptides for example, due to varied reasons. Although a growing number of PPIs have become validated drug targets, there is only a little percentage of them have been used to successfully design potent drugs.
PPIs play an important role in signaling events leading to inflammation. Many inflammatory diseases are solely based on specific signaling pathways inside the cells which are in turn driven by a prior event of a protein-protein interaction or several protein-protein interactions.
It has been clearly shown by many investigators across the world that targeting such interactions would be the best way to attenuate the signaling events and eventually the inflammation. In the last few years, various PPIs modulators have entered clinical studies, some of which have been approved for marketing, strengthening our idea that modulators targeting PPIs have broad prospects in clinical research.
The conventional methods using medicinal chemistry protocols are less effective and time-consuming for designing and identifying PPI modulators. Thus, it is necessary to develop more effective approaches for screening the PPI modulators. A wide variety of strategies including High-throughput screening (HTS), in-silico modeling, and the most recent Artificial Intelligence (AI), could multiply the results in terms of time and effort.
We would like to invite potential authors researching on topics associated with studies focused on the role of protein-protein interactions as well as targeting those in inflammatory signaling leading to multiple diseases including sepsis etc.
Articles specifically encompassing the following are welcome;
1) Artificial Intelligence (AI) in PPI-based drug discovery in immune-mediated inflammatory disease.
2) Novel cell-based high output assays for quicker screening of novel drugs against PPI's in immune-mediated inflammatory disease.
3) Novel PPI's and their therapeutic targeting in inflammation and sepsis.
Protein-protein interactions (PPIs) are involved in almost every cellular process. They represent attractive targets for modulating signaling pathways leading to disease states. However, they are challenging to target with small molecules, peptides for example, due to varied reasons. Although a growing number of PPIs have become validated drug targets, there is only a little percentage of them have been used to successfully design potent drugs.
PPIs play an important role in signaling events leading to inflammation. Many inflammatory diseases are solely based on specific signaling pathways inside the cells which are in turn driven by a prior event of a protein-protein interaction or several protein-protein interactions.
It has been clearly shown by many investigators across the world that targeting such interactions would be the best way to attenuate the signaling events and eventually the inflammation. In the last few years, various PPIs modulators have entered clinical studies, some of which have been approved for marketing, strengthening our idea that modulators targeting PPIs have broad prospects in clinical research.
The conventional methods using medicinal chemistry protocols are less effective and time-consuming for designing and identifying PPI modulators. Thus, it is necessary to develop more effective approaches for screening the PPI modulators. A wide variety of strategies including High-throughput screening (HTS), in-silico modeling, and the most recent Artificial Intelligence (AI), could multiply the results in terms of time and effort.
We would like to invite potential authors researching on topics associated with studies focused on the role of protein-protein interactions as well as targeting those in inflammatory signaling leading to multiple diseases including sepsis etc.
Articles specifically encompassing the following are welcome;
1) Artificial Intelligence (AI) in PPI-based drug discovery in immune-mediated inflammatory disease.
2) Novel cell-based high output assays for quicker screening of novel drugs against PPI's in immune-mediated inflammatory disease.
3) Novel PPI's and their therapeutic targeting in inflammation and sepsis.